ArticleASM case reports2025
Refractory pneumonia due to persistent SARS-CoV-2 infection in an immunocompromised host successfully treated with extended course nirmatrelvir/ritonavir.
Article in ASM case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immunocompromised individuals are infected with persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and often refractory to treatment. Case Summary: A 56-year-old woman undergoing chemotherapy for follicular lymphoma experienced relapsing pulmonary infiltrates and a consistently low cycle threshold value of nasal swab SARS-CoV-2 PCR over a 5-month period. Despite repeated remdesivir and glucocorticoid therapy, her respiratory symptoms worsened and progressed to respiratory failure. Viral genome analysis revealed that the variant strain at onset was XBB, whereas the strains repeatedly detected more than 2 months after onset were XBB.2.3. Conclusion: The genome analysis indicated that genomic mutations accumulate due to continuous XBB infection. The patient recovered after treatment with nirmatrelvir/ritonavir for 20 days.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.